Lantheus Secures FDA Nod for Tau PET Imaging Agent TAUKLARIFY in Alzheimer’s Disease — Lantheus Holdings, Inc.

Event summary

Lantheus Holdings received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent for Alzheimer’s disease evaluation on August 14, 2026.
Approval based on two blinded read studies involving over 500 subjects across three clinical trials.
TAUKLARIFY demonstrated Positive Percent Agreement (PPA) ranging from 68% to 88% and Negative Percent Agreement (NPA) from 93% to 99%.
Common adverse reactions included headache, nausea, injection site reactions, dizziness, and abdominal discomfort.

The big picture

Lantheus’ FDA approval of TAUKLARIFY underscores the growing importance of tau imaging in Alzheimer’s disease assessment. The diagnostic tool complements amyloid PET and other tools, aligning with the increasing demand for comprehensive disease evaluation as the prevalence of Alzheimer’s continues to rise. With over 7 million people affected in the U.S., the market potential is significant, particularly as the population ages.

What we're watching

Commercialization Strategy: Lantheus will assess the path toward broader commercial availability, aligning with partner needs and Alzheimer’s treatment landscape developments.
Market Adoption: The pace at which TAUKLARIFY integrates into clinical practice and complements existing diagnostic tools like amyloid PET imaging.
Competitive Dynamics: Whether Lantheus can sustain market leadership in tau PET imaging amid potential competing products or therapeutic advancements.